Pharmacologic therapies in the treatment of peripheral vascular disease: Clinical experience with reteplase, a third-generation thrombolytic

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. B, 2000, Pages

  Laird, John R ^a,b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; RETEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

AGE; AGED; ANGIOGRAPHY; ARTICLE; CASE REPORT; CLINICAL TRIAL; HUMAN; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASE; RISK FACTOR;

AGE FACTORS; AGED; ANGIOGRAPHY; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; RECOMBINANT PROTEINS; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034145820     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lavanier GL, Sacks D, Robinson ML. Acute limb ischemia. Emerg Med Clin NA 1992;10:103-119.
2. Neuzil DF, Edwards WH, Mulherin JL, et al. Limb ischemia: Surgical therapy in acute arterial occlusion. Am Surgeon 1997;63:270-274.
3. Cambria RP, Abbott WM. Acute arterial thrombosis of the lower extremity. Its natural history contrasted with arterial embolism. Arch Surg 1984;19:784-787.
4. Ouriel K, Veith FJ. Acute lower limb ischemia: Determinants of outcome. Surgery 1998;124:336-342.
5. Yeager RA, Moneta GL, Taylor LM, et al. Surgical management of severe acute lower extremity ischemia. J Vasc Surg 1992;15:385-393.
6. Elliott JP, Hageman JH, Szilagyi E, et al. Arterial embolization: Problems of source, multiplicity, recurrence, and delayed treatment. Surgery 1980;88: 833-845.
7. Dotter CT, Rosch J, Seaman AJ. Selective clot lysis with low-dose streptokinase. Radiology 1974;111:31-37.
8. Malone MD, Barber L, Comerota AJ. Clinical applications of thrombolytic therapy for arterial and graft occlusion. Surg Clin NA 1998;78:647-673.
9. Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994;19:1021-1030.
10. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. Ann Surg 1994;220:251-268.
11. Ouriel K, Veith FJ, Seashore AA, et al. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998;338:1105-1111.
12. Olin JW, Groan RA. Thrombolytic therapy in the treatment of peripheral arterial occlusions. Ann Emerg Med 1988;17:1210-1215.
13. Lansdale RJ, Barrage DC, Earnshaw JJ, et al. Recombinant tissue-type plasminogen activator is superior to streptokinase for local intra-arterial thrombolysis. Br J Surg 1992;79:272-274.
14. Graor RA, Olin J, Bartholomew JR, et al. Efficacy and safety of intra-arterial local infusion of streptokinase, urokinase, or tissue plasminogen activator for peripheral arterial occlusion: A retrospective review. J Vasc Med Biol 1990;2:310-315.
15. McNamara TO, Bomberger RA, Merchant RF. Intra-arterial urokinase as the initial therapy for acutely ischemic lower limbs. Circulation 1991;83(Suppl I):I106-I119.
16. Van Breda A, Katzen BT, Deutsch AS. Urokinase versus streptokinase in local thrombolysis. Radiology 1987;165:109-111.
17. Serious manufacturing deficiencies with Abbokinase prompt FDA letter to Abbott Labs. FDA Talk Paper. Food and Drug Administration, U.S. Department of Health and Human Services. July 16, 1999.
18. Product Information, Retavase®. Centocor, Inc. Malvern, Pennsylvania. December 1999.
19. Wooster MB, Luzier AB. Reteplase: A new thrombolytic for the treatment of acute myocardial infarction. Ann Pharmacother 1999;33:318-324.
20. Fischer S. Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: Lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics. Fibrinolysis & Proteolysis 1997;11:129-135.
21. Martin U, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, antistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. J Am Coll Cardiol 1992;19:433-440.
22. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alleplase infusion in acute myocardial infarction. Circulation 1995;91:2725-2732.
23. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-898.